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Nursing Advocacy and the Accuracy of Intravenous to Oral
Opioid Conversion at Discharge in the Cancer Patient
Maria Gallo
ABSTRACT
Pain is a common problem for cancer patients at home and when hospitalized. Pain
interferes with all aspects of a patient’s life including sleep, appetite, sexual desire,
emotion and productivity. The under-prescribing of opioids can lead to uncontrolled pain
in cancer patients. This study examined nursing advocacy related to pain management
and the accuracy of the intravenous (IV) to oral (PO) opioid conversion at discharge in
cancer patients.
Retrospective chart audits were done on 50 cancer patients. The physicians in the
charts surveyed who prescribed the discharge medications consisted of a mix of
hematologist/oncologists, surgeons and internists/hospitalists in a southwest Florida
community. Fifty nurses were also surveyed and asked how comfortable they are in
advocating for their patient’s pain control and how often they actually advocate for
proper pain management. This was done in the same southwest Florida hospital.
The most common cancer diagnoses of the patient subjects were colorectal cancer
and esophageal/lung cancer. The results of this study show that an overwhelming
majority of cancer patients (47 of 50), received doses that were not accurately converted
from intravenous to oral opioids at the time of discharge from the hospital. This
iv

conversion was based on the Johns Hopkins Opioid Conversion Tool. Nurses in general
reported that they are comfortable in advocating for their patients’ pain control, but more
so in more autonomous areas of practice such as intensive care.
The results were overwhelming in the direction of poor control of patient pain. This
study leads to the need for further research in the important area of pain control for
cancer patients. It also indicates the need for additional education for physicians and
nurses about pain control and opioid conversion.
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Nursing Advocacy and the Accuracy of Intravenous to Oral
Opioid Conversion at Discharge in the Cancer Patient
Chapter One
Introduction
In 2007, there were nearly 12 million new cases of cancer worldwide.
Correspondingly, there were 7.6 million cancer related deaths. (American Cancer
Society, [ACS] 2008). Cancer is one of the most feared diagnoses in the world, and pain
is one of the most feared components of the cancer diagnosis (Wess, 2007). The
mechanisms of cancer pain present physically, psychologically, socially, and spiritually,
and combined can be labeled a biopsychosocial experience (Maltoni, 2008). Opioids are
an important factor in the global treatment approach needed from early stages of the
specific disease forward. For thousands of years, opioids have been the mainstay of pain
treatment; this is still true today (Goodman & Gillman, 2007). Because pain is a
subjective experience, each patient and pain interpretation requires custom tailoring to
manage that pain (Maltoni).
The World Health Organization (WHO) developed the widely used three step
Analgesic Ladder that presents a strategy for managing cancer related pain (WHO, 2008).
While this ladder presents a succinct guide to controlling cancer pain, it does not address
titration or conversion of pain medicine in cancer patients. These groups of patients,
when hospitalized often are given intravenous opioids to control their pain. Upon release
from the hospital setting, pain control medications are most often converted to an oral,
1

transdermal or rectal route. The foundation of treatment for cancer related pain remains
opioid analgesia (Weinstein, Minggago, Buckley & Kwarcinski, 2006).
Problem Statement
While there have been numerous research studies involving conversion of oral
opioid analgesics to controlled or immediate release forms ( Wallace, Rauck, Moulin,
Thipphawong, Khanna & Tudor 2008; Weinstein, Minggao, Buckley & Kwarcinski,
2006), there is little research regarding conversion of intravenous opioids to oral opioids.
Some studies exist on the conversion to transdermal patches, but the review of literature
revealed a gap in research relative to the conversion of IV opioid to oral form upon
discharge from the hospital. The purpose of this study was to determine whether IV pain
medicine conversions to oral pain medicine was consistent with Johns Hopkins
Conversion Tool protocol, and how comfortable nurses are in advocating for appropriate
pain conversion upon the patient’s discharge from the hospital, and how frequently they
do advocate for their patients.
Research Question
The following research questions guided this study:
1) In what proportion of cancer patients is the oral dose of opioids equivalent to the
intravenous opioid dose for the discharged patient as indicated by the Johns Hopkins
Conversion Tool instrument?
2) How comfortable are nurses in advocating for patients when they discuss analgesic
doses with physicians?
3) How frequently do nurses advocate for patients’ pain control with physicians?
2

Conceptual Definitions
Pain: Pain is an unpleasant sensory and emotional experience associated with
actual or potential tissue damage or described in terms of such damage (McCance &
Huether, 2006).
ursing Advocacy- Integral component of the nurse’s efforts to encourage and
safeguard the well-being and best interests of his/her patients by doing the utmost to
ensure that patients are apprised of their rights and have ease of access of information to
make informed decisions (Vaartio, Lwino, Salantera & Suominen, 2006). For the purpose
of this study, the focus is on nursing advocacy in relation to a patient’s right to achieve
appropriate pain control.
Opioid- Broad term that refers to all compounds related to opium, derived from
the Greek word, opos, meaning “juice”. Derived from the juice of the opium poppy.
Drugs included are the natural opiates derived from opium: morphine, codeine and
thebaine. There are also numerous semi-synthetic derivatives (Goodman & Gillman). For
the purpose of this study, our focus will primarily examine conversions of
hydromorphone and morphine sulfate.
Opioid Conversion-For the purpose of this study is a change in opioid drug route
of administration with the goal of improving outcomes and establishing an opioid
regimen that is as effective as prior therapy.
Significance
With pain being the most feared part of the cancer diagnosis (Wess, 2007), it is an
essential part of the cancer treatment plan to address pain control in both the home and
3

clinical setting. Cancer pain effects 75% of patients with advanced disease and 50% of
patients at any given disease stage (Maltoni, 2007). The most common opioid conversion
tool is the Johns Hopkins Opioid Conversion Tool (Johns Hopkins, n.d.). When patients
do not get relief from a certain medication, physicians often initiate a stronger opioid.
The problem that is encountered is that physicians may calculate dosages incorrectly
during this conversion, therefore leading to poor pain control (Grossman, 2003). Using a
tool such as the Johns Hopkins Opioid Conversion Tool can assist clinicians to calculate
dosages for all forms of opioid pain medications.
Another available tool aimed at controlling cancer patients’ pain was the
American Cancer Society’s Pain Management Pocket Tool. This tool was designed to be
an easy to use reference card to assist the health care professional on pain management
principles; adjuvant analgesic medications, their starting doses, range, and indications;
opioid switching and equivalency tables; non-opioid analgesics; and side effect
management strategies (ACS, 2008).
Nursing advocacy can play an important role in dealing with pain management of
the patient at the time of discharge. Nurses’ advocating for their patients’ pain control can
help assure better patient outcomes. Studies have shown that more than 40 percent of
cancer patients have less than adequate pain relief even though therapies and
medications, both opioid and non-opioid, exist to control almost all of their pain (ACS,
2008). Nursing can advocate to help assure that the oral opioid dosages patients go home
with are equal to the intravenous hospital doses so that pain can remain adequately
controlled without any peaks or crises. This study focused on the hospital discharged
4

cancer patients, who received intravenous opioids during their hospital stay and sheds
light on nursing advocacy and its role in accurate opioid conversion.
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Chapter Two Review of Literature
This chapter presents the review of literature. First, relevant studies are presented,
and this is followed by an integrated summary of the review.
It is well documented that cancer pain is the most feared component of a cancer
diagnosis for a patient. Hospitalized cancer patients are often given intravenous opioids
to control their pain, but at the time of discharge, there is a need to convert that
intravenous opioid to an oral equivalent to continue adequate pain control. There are
several tools available to aid in that conversion.
Mercandante, Casuccio, Fulfaro, Groff, Boffi and Villari (2001) evaluated the
clinical benefits of switching from morphine to oral methadone in patients who
experienced poor analgesia or adverse effects from morphine. This prospective design
study also evaluated the clinical benefits of switching from morphine to oral methadone
in patients treated with oral morphine who experienced poor analgesia despite
progressive increases in morphine doses. This study asked the question, could switching
from morphine to methadone improve analgesia and tolerability in cancer patients? The
instrument used in this study was oral methadone administered every eight hours using
different dose ratios. Intensity of pain and adverse effects were assessed daily, and the
symptom distress score was calculated before and after switching.
The study sample consisted of fifty-two consecutive cancer patients receiving oral
morphine but with uncontrolled pain and moderate to severe opioid adverse effects. The
mean age was sixty. Twenty-eight participants were male and twenty-four female. All
6

had solid tumors. Inclusion criteria were: Uncontrolled pain not withstanding the titration
and progressive increase of morphine doses, moderate to severe opioid adverse effects
not controlled by symptomatic therapy and life expectancy longer than one month.
Exclusion criteria were brain metastases, cognitive failure, major alterations of
biochemistry, liver or renal function. Additional exclusion criteria were anticancer
treatment such as radiation and/or chemotherapy or pamidronate infusion in the three
weeks prior to the study. Two patients were excluded for poor compliance. This study
was performed at La Maddalena Cancer Center in Milan and Palermo, Italy with
inpatients from over a period of twenty-two months.
Results of the study revealed changing opioids was considered effective in eighty
percent of patients. This was measured daily using the patient’s self-reported intensity of
pain using an analog scale from zero to ten. Changing opioids was considered effective
when the visual analog scale for pain decreased to four or less. In ten patients who were
switched from methadone because of uncontrolled pain, a significant reduction in pain
intensity and an average of thirty-three percent increase in methadone doses necessary
were found after a mean of 3.5 days. Results were achieved in a mean of 3.65 days. In
thirty-two patients switched because of uncontrolled pain and morphine related adverse
effects, significant improvement was found in pain intensity (p=.005), nausea and
vomiting (p<.031), and lethargy (p<.018). It was found that eighty percent of patients
with cancer pain who were in the study because of poor pain control and/or adverse
effects, switching to oral methadone was a valid therapeutic option, but did require higher
doses of methadone to equal calculated dose ratios previously published.
7

Kornick, Santiago, Khojainova, Primavera, Payne and Manfredi (2003) evaluated
and described the safety and effectiveness of a method for converting hospitalized
patients with cancer related pain from IV to transdermal fentanyl. This was a prospective
design study of fifteen consecutive cancer patients at the Palliative Care Service of a
large cancer center in an inpatient setting over a period of twelve weeks. Data was
recorded on each participant prior to the application of the transdermal patch. This data
was pain diagnosis, demographics, cancer diagnosis, serum creatinine and total bilirubin
resulted in the prior seven days, and PCA dosage and lockout time. The primary method
of obtaining information was through self-reports. Patients’ pain level intensity ratings
were measured on a verbal numeric ratings scale (NRS). This scale had eleven points
ranging from zero (no pain) to ten (worst pain ever felt). Patients were also asked to
answer the question, “Is your level of pain relief acceptable (yes or no)?” Pain intensity
was also monitored by observation of no change in PCA rate for more than twelve hours
and no change in the dosage of demand boluses available by PCA for more than twelve
hours.
No statistically significant change in hourly PCA administration was identified at
the six-hour intervals compared with administration immediately prior to patch
application (P<0.05). Significant decrease in pain intensity was found at twelve-hour post
patch application compared with ratings prior to patch application (P=0.024). Significant
decreases in sedation were identified at six days compared with ratings prior to patch
application (P=0.026). Twenty-four hours post patch application none of the participants
had a pain intensity rating greater than five at rest or greater than six with activity.
8

According to the statistically significant decrease in resting pain, therapeutic blood levels
were reached approximately twelve to sixteen hours after initial application of the patch.
Due to this action, the patch was not recommended alone for acute cancer pain. For acute
pain, crisis short acting oral opioids should be initiated prior to the initiation of the
transdermal fentanyl patch. All fifteen patients in the study were switched successfully
from IV to transdermal Fentanyl using a 1:1 conversion ratio. Pain remained well
controlled and patients remained hemodynamically stable.
Weinstein, Minggao, Buckley and Kwarcinski (2006) compared the safety and
efficacy of once daily-extended release hydromorphone HCL capsules with immediate
release hydromorphone HCL tablets administered four times daily in the treatment of
persistent moderate to severe cancer and noncancer related pain. There were 343
participants total. Two-hundred seventy-two had cancer pain. The mean age was 57.8.
Fifty-one percent were women; forty-nine percent were men. Eighty-seven percent were
white. All patients were older than twenty-two years of age. One-hundred twenty-six
patients discontinued study participation during titration for a variety of reasons. Patients
were transitioned to extended release (ER) hydromorphone HCl from their prestudy
opioid analgesics and then underwent titration for four to twenty-one days to an
individualized dose. All patients discontinued their prestudy opioids and received openlabel ER hydromorphone. Calculation of dose was based on the aggregate dose of
previous opioids and rounded to a multiple of the twelve-milligram capsule strength.
Investigator’s judgment of recent pain intensity was also considered when rounding up or
down. After the initial twenty-four hour titration, doses were then titrated on an as
9

needed basis. Patients kept a diary where they recorded their pain ratings four times a day
following the average pain intensity (API) scale. This scale is from zero to ten, with zero
being no pain and ten being the worst pain possible. Patients also recorded time and
number of ER hydromorphone tablets taken per dose and any concomitant meds and
adverse effects they encountered. Content of diary was reviewed each night via telephone
by staff.
In this prospective evaluation of conversion and titration, a conversion ratio of
8:1mg of prestudy opioid to oral ER hydromorphone HCl was found to be clinically
useful in patients with persistent moderate to severe cancer related or noncancer related
pain. At baseline the API score was 5.3, mean API scores were 4.7 after the first fortyeight hours and 3.4 by the end of titration.
Wallace, Rauck, Moulin, Thipphawong, Khanna and Tudor (2008) proposed the
question, can conversion from standard opioid therapy to once daily oral extended release
hydromorphone produce improved pain ratings in patients with chronic cancer pain?
This open-label study involved three phases; stabilization, conversion and titration. The
instrument used was the Brief Pain Inventory (BPI) with zero being no pain and ten being
the worse pain felt. Pain relief was rated on a scale of zero percent (no relief) to onehundred percent (complete relief). Interference of activities of daily living (ADL’s) was
rated on a scale of zero to ten. A five-point scale rated overall effectiveness one, poor;
two, fair; three, good; four, very good; and five, excellent. No alpha coefficient was
reported.
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This study included of 148 patients with chronic cancer pain from six medical
centers. Twenty-one patients withdrew prior to receiving study medication. Eighty-five of
the patients completed the study. Thirty patients withdrew during titration, twelve during
maintenance and four patient deaths were reported, unrelated to the study.
Results of this study found dose stabilization was achieved in 94% of patients
who received the study medication. In 77%, stabilization was achieved with no titration
steps. Mean BPI pain intensity ratings and interference scores decreased significantly (p<
.05) after hydromorphone treatment when compared to the pretreatment values. In
pretreatment versus endpoint general activity was 4.6 vs 3.8; mood 4.5 vs 3.3; walking
ability 4.6 vs 4.0; normal work 5.3 vs 4.2; relations with others 3.7 vs 3.0; sleep 4.1 vs
3.2; and enjoyment of life 4.8 vs 3.8. Vital signs remained stable and adverse events
were as expected in patients receiving opioid agonists, but specifics were not disclosed.
Ginsberg, Sinatra, Adler, Crews, Hord and Laurito (2003) assessed the
conversion factors utilized by physicians to transfer postoperative patients from
intravenous opioids to oral controlled-release oxycodone and the subsequent analgesic
effectiveness in a multicenter study. This study asked the question, could conversion to
oral controlled-release oxycodone from IV opioid analgesia be effective in the
postoperative setting? The open-labeled usual use study asked participants to rate pain
intensity using an eleven-point numeric rating scale (0-10). During the study, while
hospitalized, patients rated their pain intensity just before conversion to oxycodone CR
and then every six hours.
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Patients also rated pain intensity during activities such as walking, bathing,
changing position and physical therapy. After discharge for up to seven days, patients
were contacted by telephone approximately six hours after their morning dose to obtain
current pain level ratings of intensity. At completion of the study, they rated their overall
acceptance of the medication.
The results of the study found that, given twelve hours following orthopedic,
gynecologic and abdominal surgery, an initial daily oral oxycodone CR dose provided
adequate pain control during the subsequent twelve-hour dosing interval and for a
maximum of seven days. This dose was calculated by multiplying the amount of IV
morphine used in the previous twenty-four hours by a conversion factor of 1.2, on
average. No paralytic ileus was found on patients tolerating oral medications.
Integrated Summary
The literature review provided a review of the conversion from intravenous
opioids to oral opioids at the time of discharge. The commonality among many of these
studies was the use of the fentanyl patch for conversion. It was the lack of data available
that supports the need for further studies to assure that patients have their pain managed
to the best possible level and the inclusion of nursing advocacy in the assistance of this
task.
Three studies were open-label studies, one being repeated dose and single
treatment. Three were multicenter trials. Two were prospective nonrandomized trials.
Study sample sizes ranged from fifteen to three-hundred and forty-two participants. Ages
ranged from eighteen to seventy years old. While participants in all studies were split
12

almost evenly female/male, the primary race in the studies was Caucasian, limiting the
generalizability of these studies. Brief Pain Inventory (BPI) or average pain intensity
(API) scale was used in all five studies. These are eleven-point scales from zero being no
pain to eleven being the worse pain imaginable. Adverse events were monitored and
study discontinuations were documented. Although research was found that supported
standardized titration of opioids, no studies were found of nursing advocacy related to
pain management or opioid conversion.
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Chapter Three Methods
This chapter presents the study methods that were used. First, the sample is
described. This is followed by the instruments used to gather data. Then, procedures are
presented including approvals. Finally, the plan for data analysis is detailed.
Setting and Sample
The sample for this study was drawn from charts of fifty inpatients with cancer
and fifty registered nurses. Subjects were obtained from retrospective chart reviews in a
community hospital in southwest Florida. Data from the study was collected during the
months of October 2008 through May 2009.
Inclusion Criteria
Inclusion criteria for this study were as follows: patient participants had a cancer
diagnosis with pain and were admitted with a condition related to their cancer. Patients
were eighteen years or older; and were receiving intravenous opioids while in the
hospital; and were either male or female.
Nurse participants were full-time hospital registered nurses. All participants read,
wrote and spoke English. This data was obtained by survey during the month of June
2009 in the same community hospital in southwest Florida.
Exclusion Criteria
Patient participants admitted for problems unrelated to their cancer diagnosis were
excluded. Also excluded were patients’ under the age of eighteen; and patients not
receiving intravenous opioids.
14

Instrumentation
Chart Audit for Pain
A chart audit for pain was developed to review the patient records twenty-four
hours prior to discharge (Appendix A). The chart audit tool documented what IV opioids
the patient was receiving in the twenty-four hours prior to discharge, and then
documented the oral opioid dose prescribed for the patient for home use. Demographics
were recorded to include sex, age, race, ethnicity, type of cancer, reason for
hospitalization and type and location of pain.
ursing Advocacy
The tool for assessing nursing advocacy in opioid conversion at the time of
discharge was a questionnaire consisting of two questions. One question asked nursing
staff about their feelings of comfort in addressing with the physician, the pain needs of
their patient’s at the time of discharge. Another question asked how often they actually
do advocate on their patient’s behalf. This tool documented their responses and
perceptions related to their own advocacy (Appendix B).
Johns Hopkins Opioid Conversion Tool
This tool was designed to facilitate the rational conversion of one opioid regimen
to an approximately equianalgesic dose of another. Medical students, house officers,
pharmacists, nurses, oncology fellows, and attending physicians in the Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins have used this program for years to
accurately calculate opioid conversions.
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Institutional Approvals
Approval was obtained from the hospital in which this study was conducted and
the Institutional Review Board (IRB) with a waiver for informed consent (Appendix C).
There are no identified risks to the proposed subjects of this study given that nursing
questionnaires were done anonymously and patient charts were used only to gather data.
No patient consent was needed for retrospective chart reviews, and nurses completed
questionnaires anonymously; therefore, consent was implied if the completed the forms.
Procedures
Patient participants were identified through oncology physician hospital rosters
and medical record review. Cancer diagnosis was confirmed during medical record
review. The author conducted chart audits and compared what IV opioid the patient was
receiving in the twenty-four hours prior to discharge and what oral opioid that patient was
sent home with. This audit information was then used to calculate equivalent doses using
the Johns Hopkins Opioid Conversion Tool. This evaluated if appropriate conversion was
calculated at the time of discharge. Nurse participants were given questionnaires and
given two weeks to complete and return them. Privacy was maintained by submission of
anonymous questionnaires via locked drop box. Participants were not compensated in any
way for their participation.
Data Analysis
Demographic data were analyzed to describe the patient, physician and nurse
subjects. Data were analyzed using frequencies, percentages, means and standard
deviations.
16

Data was analyzed to answer the research questions. Research question 1 asked;
in what proportion of cancer patients is the oral dose of opioids equivalent to the
intravenous opioid dose for the discharged patient as indicated by the Johns Hopkins
Conversion Tool instrument? This question was answered using frequencies, percentages,
means and standard deviations. Research question 2 asked; how comfortable are nurses to
advocate for patients when they discuss analgesic doses with physicians? This question
was answered using frequencies, percentages, means and standard deviations. Research
question 3 asked; how frequently do nurses advocate for patients’ pain control with
physicians? This question was answered using frequencies, percentages, means and
standard deviations.
The data gathered in the fifty patient chart audits was used to evaluate whether
physicians were prescribing the recommended opioid dose upon discharge from the
hospital. This calculation was based on the Johns Hopkins Opioid Conversion Tool.
Number and percent of patients receiving appropriate discharge doses of opioids was
reported. This information was then converted to percentages of patients whose opioids
were prescribed correctly according to the Hopkins Tool.
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Chapter Four
Results, Discussion, and Conclusions
This chapter presents the outcomes and findings from the research study conducted at
a community hospital in southwest Florida. It also discusses results and implications of
the findings and limitations of the study.
Results
Patients Demographic Data
The patient sample consisted of 50 subjects, 23 male and 27 female, ranging in age
from 28 to 91 with a mean age of 68.9 (SD=13.6). The majority of patients were
Caucasian, with four subjects being African American. All patient subjects had a cancer
diagnosis (Table1).
Table 1. Frequency and Percent of Participants’ Demographic Characteristics
Demographics

Frequency

Percent

Female

27

54.0

Male

23

46.0

Caucasian

46

92.0

African American

4

8.0

Gender

Race
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Admitting diagnosis of subjects varied greatly. Forty-eight percent of subjects had an
admitting diagnosis related to abdominal and/or pelvic complaints, followed by 12%
being admitted related to infection, 12% related to respiratory distress, 10% neurological
issues, 8% weakness, and 10% varied general complaints.
Location of pain was primarily in the abdominal area at 54% with musculoskeletal
complaints at 22%, followed chest complaints at 8% and various other complaints at 6%.
Source of pain was most prevalent from metastatic disease at 24% followed by
postoperative sources at 22% and unknown sources at 22% (Table 2).
Table 2. Frequency and Percent of Location and Source of Pain
Frequency

Percent

Abdomen/Groin

27

54.0

Musculoskeletal

11

22.0

Chest/Neck

4

8.0

Other

8

6.0

Metastatic Disease

12

24.0

Post Operative

11

22.0

Gastrointestinal

7

14.0

Musculoskeletal

6

12.0

Infection

3

6.0

Other/Unknown

11

22.0

Location of Pain

Source of Pain
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Patient’s cancer diagnoses varied with 20% of patients having lung or esophageal
cancer, and 20% having colorectal cancer (Table 3).
Table 3: Cancer Diagnosis
Cancer Diagnosis

Frequency

Percent

Colorectal

10

20.0

Esophageal/Lung

10

20.0

Pancreatic/Liver

5

10.0

Kidney/Bladder

4

8.0

Breast

4

8.0

Testicular/Ovarian

4

8.0

Leukemia/Lymphoma

3

6.0

Prostate

3

6.0

Other

7

14.0

Physician Sample
The physician sample of this study included three specialties; hematology/oncology
specialists, surgeons, and internal medicine/hospitalists. The groups of
hematology/oncology doctors were all from private practice, the surgeons varied,
including general surgeons, urologists and neurosurgeons. The hospitalists and internists
were general practice physicians (Table 4).
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Table 4. Frequency and Percentage of Physicians by Specialty
Physician Specialty

Frequency

Percent

Hospitalist/Internist

20

40.0

Hematology/Oncology

17

34.0

Surgeons

12

24.0

Opioid Conversion
The intravenous opioids prescribed in the hospital setting was either hydromorphone
or morphine sulfate. Of the 50 patient subjects that were studied, 47 (94%) subjects were
under-prescribed oral opioids at the time of discharge, 2 (4%) were over-prescribed oral
opioids at the time of discharge, and one (2%) was discharged on the appropriate oral
opioid equivalent (Table 5).
Table 5. Frequency and Percentage of Conversion Results
Validity of Conversion

Frequency

Percent

Under

47

94.0

Over

2

4.0

Correct

1

2.0

ursing Sample
This study also involved nurses and their comfort level advocating for their patients’
pain control. Twenty-two percent of subjects studied were oncology nurses, 24%
cardiac/stroke nurses, 18% ICU nurses, 14% medical nurses, 12% surgical nurses, and
10% rehab nurses. Surgical nurses reported feeling most comfortable advocating for their
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patients’ pain control, on a 0-10 scale, with a mean of 10 (Appendix B). They were
followed by ICU nurses with a mean of 9.89 and oncology nurses with a mean of 9.27.
Nurses who felt that they advocate for their patients the most are surgical and ICU nurses
with a mean of 10, then oncology nurses with a mean of 8.82 and additional disciplines
with means below 7. Overall comfort mean was 8.80, and the overall advocacy mean was
7.98 (Table 6).
Table 6. Means and Standard Deviations for Comfort and Advocacy by Nursing
Specialty
Nursing Specialty
N
Mean
SD
Comfort
Oncology

11

9.27

1.009

ICU

9

9.89

.333

Surgical

6

10.00

.000

Cardiac/Stroke

11

8.00

1.549

Medical

7

8.00

2.082

Rehab

5

8.00

2.121

Oncology

11

8.82

1.401

ICU

9

10.00

.000

Surgical

6

10.00

.000

Cardiac/Stroke

11

6.45

2.115

Medical

7

6.57

1.618

Rehab

5

6.20

1.304

Advocacy
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Table 7. Frequency and Percentage of Participant Scores on Comfort and Advocacy
1-10 Scale Score

Frequency

Percent

10

27

54.0

9

6

12.0

8

7

14.0

7

4

8.0

6

2

4.0

5

4

8.0

10

21

42.0

9

2

4.0

8

9

18.0

7

5

10.0

6

5

10.0

5

3

6.0

4

4

8.0

3

1

2.0

Comfortable

Advocacy
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Discussion
Opioid Conversion
The patient sample largely consisted of middle-class, white, non-Hispanic topic. The
sample was limited by the lack of non-white subjects, but was represented well in the
equal distribution of male and female subjects.
Forty-seven out of the 50 subjects received inadequate opioid conversion at discharge.
All subjects were receiving either intravenous morphine sulfate or hydromorphone as
inpatients and when converted to oral opioids at discharge only one patient received an
appropriate prescription that was equivalent to the IV dose. This lone subject received a
prescription for the correct opioid dose by an oncologist. Interestingly, two subjects were
slightly over-prescribed opioids at the time of discharge. Both these subjects had the
opioids prescribed by hospitalists. Because of the overwhelming number of subjects
who were under prescribed, having a larger sample would not have changed the outcome
of this study. The results of the study cannot be compared to other studies, due to the lack
of data on this subject. Intravenous opioid conversion to oral form was grossly underprescribed in this sample of patients.
When a patient was discharged home from the hospital on a sub-therapeutic level
of opioid, the patient’s unmet pain needs then became an even greater challenge for
patients and their families. This uncontrolled pain can lead to patients missing treatment
and follow up appointments, patient as well as family fatigue, and poorer outcomes. The
quality of the patients’ lives and that of their families are adversely affected. This cascade
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of unmet pain control needs helps to solidify the societal belief that cancer patients
inevitably suffer and die in horrific pain (Wess, 2007).
ursing Comfort and Advocacy
The survey showed that ICU nurses and surgical nurses not only reported being
the most comfortable advocating for their patients’ pain control, but they also reported
advocating most frequently to the physicians for pain control needs. Oncology nurses
were comfortable advocating for their patients, but less than that of ICU and surgical
nurses. They also reported advocating less for their patients. It is possible that ICU
nurses, perhaps because of their autonomy, tend to be very confident nurses and interact
with physicians more frequently. Cardiac and rehabilitation nurses are least comfortable
advocating for their patients’ pain control and advocate less often than other nurses. This
might be expected because of their work experience in dealing with opioids much less
frequently.
Limitations
Having a more representative number of non-white subjects would have
provided additional data to query if race had any relevance in the amount and type of
opioid prescribed. . One limitation identified is that the survey could have expanded on
why nurses did or did not feel comfortable advocating for their patients’ pain control at
discharge and what physician traits make them more likely to advocate for their patients.
Other limitations include the study being done in one hospital, therefore limiting the
geographical area in which the data for the chart audits and nursing surveys were
collected. In addition, all data were collected using investigator-designed tools with
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unknown validity and reliability. Also, it should be noted that this was self-report data
and could have been biased in some way.
Implications for ursing
The findings in this two-part study have several implications for nursing practice.
Because patient advocacy is the primary role of the nurse it is important for nurses to
obtain the skills and confidence needed to advocate for their patients’ pain control to all
physicians at the time of discharge, as well as during their hospital stay. In order to
advocate in this way, nurses must learn equi-analgesic dosing methods themselves.
Advocacy also should be a strong part of the nursing curriculum, in basic nursing
programs and advanced practice programs. Physicians often prescribe the same opioid
dosages to patients without regard to the intravenous opioid dose the patients are
receiving in the hospital. It is within the nurses’ scope of practice and abilities to
approach the physician and bring to their attention the intravenous opioid dose the patient
was receiving. By providing this information clearly and succinctly, the physician may be
more apt to calculate a more suitable dose of oral opioid for the patient at time of
discharge. This will also help to foster a collaborative relationship between the physicians
and the nurses. This in turn will improve patient outcomes and increase the overall
quality of the patient care delivered. Further nursing research could also investigate what
obstacles nurses face when trying to advocate for their patients’ pain control. This
information could be analyzed to attempt to increase the comfort levels of nurses as
advocates and that would lead to an overall improvement in not only oncology patient
care, but also patient care in general.
26

Conclusions
Physicians, oncologists included, grossly under prescribed oral opioids at the time
of discharge from the hospital setting. No relationship was found between medical
specialty and prescription accuracy. Findings suggest that further research is needed
focusing on the provision of tools or new avenues to assist in the conversion of
intravenous to oral opioids upon discharge in the cancer patient. This study also indicates
the need for addition pain control education in medical and nursing schools, with a focus
on opioid conversions.
Nurses, for the most part, felt comfortable in advocating for their patients’ pain
control and directly advocated for their patients regularly. However, not all nursing
specialties had the same comfort level, or advocated as often as others do. Findings
suggest that additional support may be required at the hospital level to help increase
advocacy in relation to pain control between nurses and physicians.
Recommendations for future research
Further research in these areas should include subjects from different racial
backgrounds. Ethnic origin also may provide information that would assist in seeing a
trend to over or under prescribe a certain ethnicity or race. An interesting direction in
research would be to focus on physicians and their perceptions of obstacles in opioid
prescribing and what limits their judgment in prescribing more accurately based on the
patients intravenous usage. Future studies should include patient assessments of pain in
the hospital and at home to help confirm the efficacy of the opioid dose or lack of it. In
addition, nursing advocacy studies of this type should evaluate whether nurses are able to
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make accurate opioid conversions. More studies regarding nurses and advocacy are
needed to identify what keeps nurses from speaking up on behalf of their patients. With
this identified, the overall outcome of patient care would improve greatly in relation to
pain control in the oncology patient.
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Appendix A: Chart Audit Tool
Chart Audit Tool

Chart Number___________________Admission Date__________
Cancer DX____________________________________________
Admitting DX__________________________________________
Sex________Age_______Race_________
Type and Source of Pain ________________________________
___________________________________
In-patient opioid RX_______________________________________
________________________________________________________
Discharge opioid RX________________________________________
_________________________________________________________
Ordering Physician Specialty_________________________________
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Appendix B: Nursing Survey
Nursing Survey

1. On a 0 to 10 scale (from not at all with ANY physician to - completely comfortable with ALL physicians) rank how
comfortable you are in advocating for your patients pain
control to the physicians you work with.
__________

2. On a 0 to 10 scale (from never with any physicians - to
all the time with all physicians) HAVE you advocated for
your patients pain control with physicians you deal with.
__________
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